Entrectinib Stocks List
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
GURU | C | Global X Top Guru Holdings Index ETF | 1.3 | |
PTH | D | Invesco DWA Healthcare Momentum ETF | 1.29 | |
DWAS | C | PowerShares DWA SmallCap Technical Leaders Portfolio | 1.17 | |
CNCR | D | Loncar Cancer Immunotherapy ETF | 1.03 | |
XBI | D | SPDR S&P Biotech ETF | 0.86 |
Compare ETFs
- Entrectinib
Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).The most common side effects include tiredness, constipation, dysgeusia (taste disturbances), edema (swelling with fluid retention), dizziness, diarrhea, nausea (feeling sick), dysesthesia (unpleasant and abnormal feeling when touched), dyspnea (difficulty breathing), anemia (low red blood cell count), increased weight, increased blood creatinine (possible sign of kidney problems), pain, cognitive disorders (problems with ability to think, learn and remember), vomiting, cough, and fever.It was approved for medical use in the United States in August 2019, in Australia in May 2020, and in the European Union in July 2020.
Popular Now
Recent Comments
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
From the Blog
Featured Articles